{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:53:41Z","timestamp":1792270421005,"version":"4.4.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:sec>\n<jats:title>Context<\/jats:title>\n<jats:p> Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p> To investigate the safety and efficacy of Tesomet (0.5 mg tesofensine\/50 mg metoprolol) in adults with hypothalamic obesity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p> Twenty-one adults with hypothalamic obesity (16 females) were randomized to Tesomet (0.5 mg\/50 mg) or placebo for 24 weeks. Patients also received diet\/lifestyle counselling. The primary endpoint was safety; secondary endpoints included measures of body weight, appetite scores, quality of life, and metabolic profile.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p> Eighteen patients completed 24 weeks. Consent withdrawal, eligibility, and serious adverse events (SAE) unrelated to treatment resulted in dropouts. One patient experienced a Tesomet-related SAE of exacerbated pre-existing anxiety leading to treatment discontinuation. Tesomet-related adverse events were otherwise mostly mild and included sleep disturbances (Tesomet 50%, placebo 13%), dry mouth (Tesomet 43%, placebo 0%), and headache (Tesomet 36%, placebo 0%). No significant differences in heart rate or blood pressure were observed between groups. Compared to placebo, Tesomet resulted in additional mean (95% CI) weight change of \u22126.3% ((\u221211.3; \u22121.3); <jats:italic>P<\/jats:italic>\u2009\u2009=\u20090.017), increased the number of patients achieving \u22655% weight loss (Tesomet 8\/13, placebo 1\/8; <jats:italic>P<\/jats:italic>\u2009\u2009=\u20090.046), and tended to augment the reduction in waist circumference by 5.7 cm ((\u22120.1; 11.5); <jats:italic>P<\/jats:italic>\u2009\u2009=\u20090.054).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p> Tesomet was welltolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-21-0972","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T17:35:10Z","timestamp":1647452110000},"page":"687-700","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":44,"title":["Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity"],"prefix":"10.1093","volume":"186","author":[{"given":"Kim","family":"Huynh","sequence":"first","affiliation":[{"name":"Department of Medical Endocrinology and Metabolism PE 2131\/2, Copenhagen University Hospital (Rigshospitalet), Copenhagen \u00d8, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-0821","authenticated-orcid":true,"given":"Marianne","family":"Klose","sequence":"additional","affiliation":[{"name":"Department of Medical Endocrinology and Metabolism PE 2131\/2, Copenhagen University Hospital (Rigshospitalet), Copenhagen \u00d8, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Krogsgaard","sequence":"additional","affiliation":[{"name":"Saniona A\/S, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Drejer","sequence":"additional","affiliation":[{"name":"Saniona A\/S, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Byberg","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Copenhagen, Copenhagen N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hvidovre University Hospital, University of Copenhagen, Hvidovre, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen, Copenhagen N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-7364","authenticated-orcid":true,"given":"Faidon","family":"Magkos","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Frederiksberg C, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellatif","family":"Aharaz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Slagelse Hospital, Slagelse, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Edsberg","sequence":"additional","affiliation":[{"name":"Saniona A\/S, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Tfelt-Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Heart Centre, Copenhagen University Hospital (Rigshospitalet), Copenhagen \u00d8, Denmark"},{"name":"Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne Vernon","family":"Astrup","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Frederiksberg C, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":true,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Medical Endocrinology and Metabolism PE 2131\/2, Copenhagen University Hospital (Rigshospitalet), Copenhagen \u00d8, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen, Copenhagen N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"bib1","series-title":"Klinische Padiatrie","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/s-2001-16855","article-title":"Obesity after childhood craniopharyngioma \u2013 German multicenter study on pre-operative risk factors and quality of life","volume":"213","author":"M\u00fcller","year":"2001","unstructured":"M\u00fcller HLBueb KBartels URoth CHarz KGraf NKorinthenberg RBettendorf MK\u00fchl JGutjahr PObesity after childhood craniopharyngioma \u2013 German multicenter study on pre-operative risk factors and quality of life. Klinische Padiatrie2001213244\u2013249. (https:\/\/doi.org\/10.1055\/s-2001-16855)10.1055\/s-2001-16855"},{"key":"bib2","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/EJE-15-0422","article-title":"Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma","volume":"173","author":"Hoffmann","year":"2015","unstructured":"Hoffmann ABootsveld KGebhardt UDaubenb\u00fcchel AMMSterkenburg ASM\u00fcller HL. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. European Journal of Endocrinology2015173389\u2013397. (https:\/\/doi.org\/10.1530\/EJE-15-0422)10.1530\/EJE-15-0422"},{"key":"bib3","series-title":"Pediatric Obesity","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijpo.12076","article-title":"Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours","volume":"11","author":"Haliloglu","year":"2016","unstructured":"Haliloglu BAtay ZGuran TAbal\u0131 SBas STuran SBereket A. Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours. Pediatric Obesity201611383\u2013388. (https:\/\/doi.org\/10.1111\/ijpo.12076)10.1111\/ijpo.12076"},{"key":"bib4","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-012-0428-2","article-title":"Mortality and morbidity in adult craniopharyngioma","volume":"16","author":"Erfurth","year":"2013","unstructured":"Erfurth EMHolmer HFjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary20131646\u201355. (https:\/\/doi.org\/10.1007\/s11102-012-0428-2)10.1007\/s11102-012-0428-2"},{"key":"bib5","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3897","article-title":"Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence","volume":"83","author":"B\u00fclow","year":"1998","unstructured":"B\u00fclow BAttewell RHagmar LMalmstr\u00f6m PNordstr\u00f6m CHErfurth EM. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. Journal of Clinical Endocrinology and Metabolism1998833897\u20133904. (https:\/\/doi.org\/10.1210\/jcem.83.11.5240)"},{"key":"bib6","series-title":"Frontiers in Endocrinology","article-title":"Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits","volume":"2","author":"Roth","year":"2011","unstructured":"Roth CLHypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Frontiers in Endocrinology20112 49. (https:\/\/doi.org\/10.3389\/fendo.2011.00049)"},{"key":"bib7","series-title":"Endocrine Reviews","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"van Iersel","year":"2019","unstructured":"van Iersel LBrokke KEAdan RAHBulthuis LCMvan den Akker ELTvan Santen HM. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review. Endocrine Reviews201940193\u2013235. (https:\/\/doi.org\/10.1210\/er.2018-00017)10.1210\/er.2018-00017"},{"key":"bib8","series-title":"Journal of Neurosurgery","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","article-title":"The descriptive epidemiology of craniopharyngioma","volume":"89","author":"Bunin","year":"1998","unstructured":"Bunin GRSurawicz TSWitman PAPreston-Martin SDavis FBruner JM. The descriptive epidemiology of craniopharyngioma. Journal of Neurosurgery199889547\u2013551. (https:\/\/doi.org\/10.3171\/jns.1998.89.4.0547)10.3171\/jns.1998.89.4.0547"},{"key":"bib9","series-title":"Neuro-Oncology","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","article-title":"Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program","volume":"14","author":"Zacharia","year":"2012","unstructured":"Zacharia BEBruce SSGoldstein HMalone HRNeugut AIBruce JN. Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro-Oncology2012141070\u20131078. (https:\/\/doi.org\/10.1093\/neuonc\/nos142)10.1093\/neuonc\/nos142"},{"key":"bib10","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1210\/jc.2003-031751","article-title":"Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma","volume":"89","author":"M\u00fcller","year":"2004","unstructured":"M\u00fcller HLEmser AFaldum ABruhnken GEtavard-Gorris NGebhardt UOeverink RKolb RS\u00f6rensen N. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. Journal of Clinical Endocrinology and Metabolism2004893298\u20133305. (https:\/\/doi.org\/10.1210\/jc.2003-031751)10.1210\/jc.2003-031751"},{"key":"bib11","series-title":"Child\u2019s Nervous System","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00381-020-04877-z","article-title":"Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma","volume":"37","author":"Fouda","year":"2021","unstructured":"Fouda MAZurakowski DScott RMMarcus KJManley PEUllrich NJCohen LEGoumnerova LC. Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma. Child\u2019s Nervous System202137403\u2013410. (https:\/\/doi.org\/10.1007\/s00381-020-04877-z)10.1007\/s00381-020-04877-z"},{"key":"bib12","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1530\/EJE-12-0792","article-title":"Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic","volume":"168","author":"Steele","year":"2013","unstructured":"Steele CACuthbertson DJMacFarlane IAJavadpour MDas KSVGilkes CWilding JPDaousi C. Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. European Journal of Endocrinology2013168501\u2013507. (https:\/\/doi.org\/10.1530\/EJE-12-0792)10.1530\/EJE-12-0792"},{"key":"bib13","series-title":"Obesity","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/oby.2009.491","article-title":"Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity","volume":"18","author":"Rakhshani","year":"2010","unstructured":"Rakhshani NJeffery ASSchulte FBarrera MAtenafu EGHamilton JK. Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity. Obesity2010181768\u20131774. (https:\/\/doi.org\/10.1038\/oby.2009.491)10.1038\/oby.2009.491"},{"key":"bib14","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"e4734","article-title":"Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study","volume":"106","author":"van Santen","year":"2021","unstructured":"van Santen SSWolf PKremenevski NBoguszewski CLBeiglb\u00f6ck HFiocco MWijnen MWallenius VRvan den Heuvel-Eibrink MMvan der Lely AJBariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study. Journal of Clinical Endocrinology and Metabolism2021106e4734\u2013e4745. (https:\/\/doi.org\/10.1210\/clinem\/dgab518)"},{"key":"bib15","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2265.2012.04409.x","article-title":"Bariatric surgery for morbid obesity in craniopharyngioma","volume":"78","author":"Weismann","year":"2013","unstructured":"Weismann DPelka TBender GJurowich CFassnacht MThalheimer AAllolio B. Bariatric surgery for morbid obesity in craniopharyngioma. Clinical Endocrinology201378385\u2013390. (https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04409.x)10.1111\/j.1365-2265.2012.04409.x"},{"key":"bib16","series-title":"Obesity Reviews","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1467-789X.2009.00614.x","article-title":"A systematic review of drug absorption following bariatric surgery and its theoretical implications","volume":"11","author":"Padwal","year":"2010","unstructured":"Padwal RBrocks DSharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obesity Reviews20101141\u201350. (https:\/\/doi.org\/10.1111\/j.1467-789X.2009.00614.x)10.1111\/j.1467-789X.2009.00614.x"},{"key":"bib17","series-title":"Current Drug Metabolism","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2174\/138920012803341339","article-title":"Vitamin, mineral, and drug absorption following bariatric surgery","volume":"13","author":"Sawaya","year":"2012","unstructured":"Sawaya RAJaffe JFriedenberg LFriedenberg FK. Vitamin, mineral, and drug absorption following bariatric surgery. Current Drug Metabolism2012131345\u20131355. (https:\/\/doi.org\/10.2174\/138920012803341339)10.2174\/138920012803341339"},{"key":"bib18","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1210\/jc.2003-030870","article-title":"Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarism","volume":"88","author":"Mersebach","year":"2003","unstructured":"Mersebach HSvendsen OLAstrup AFeldt-Rasmussen U. Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarism. Journal of Clinical Endocrinology and Metabolism2003885689\u20135695. (https:\/\/doi.org\/10.1210\/jc.2003-030870)10.1210\/jc.2003-030870"},{"key":"bib19","series-title":"Pediatric Research","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1203\/pdr.0b013e3180332cd6","article-title":"Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma","volume":"61","author":"Roth","year":"2007","unstructured":"Roth CLHunneman DHGebhardt UStoffel-Wagner BReinehr TM\u00fcller HL. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatric Research200761496\u2013501. (https:\/\/doi.org\/10.1203\/pdr.0b013e3180332cd6)10.1203\/pdr.0b013e3180332cd6"},{"key":"bib20","series-title":"Frontiers in Endocrinology","article-title":"Effects of methylphenidate on weight gain and food intake in hypothalamic obesity","volume":"2","author":"Elfers","year":"2011","unstructured":"Elfers CTRoth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Frontiers in Endocrinology20112 78. (https:\/\/doi.org\/10.3389\/fendo.2011.00078)"},{"key":"bib21","series-title":"Pediatric Blood and Cancer","article-title":"Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity","volume":"67","author":"Horne","year":"2020","unstructured":"Horne VEBielamowicz KNguyen JHilsenbeck SLindsay HSonabend RWood ACOkcu FSisley S. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatric Blood and Cancer202067 e28379. (https:\/\/doi.org\/10.1002\/pbc.28379)"},{"key":"bib22","series-title":"Obesity Facts","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","article-title":"Treatment of hypothalamic obesity with dextroamphetamine: a case series","volume":"12","author":"Denzer","year":"2019","unstructured":"Denzer CDenzer FLennerz BSVollbach HLustig RHWabitsch M. Treatment of hypothalamic obesity with dextroamphetamine: a case series. Obesity Facts20191291\u2013102. (https:\/\/doi.org\/10.1159\/000495851)10.1159\/000495851"},{"key":"bib23","series-title":"Archives of Pediatrics and Adolescent Medicine","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/archpedi.156.9.887","article-title":"The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma","volume":"156","author":"Mason","year":"2002","unstructured":"Mason PWKrawiecki NMeacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Archives of Pediatrics and Adolescent Medicine2002156887\u2013892. (https:\/\/doi.org\/10.1001\/archpedi.156.9.887)10.1001\/archpedi.156.9.887"},{"key":"bib24","series-title":"Journal of Pediatric Endocrinology and Metabolism","first-page":"129","article-title":"Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury","volume":"19","author":"Ismail","year":"2006","unstructured":"Ismail DO\u2019Connell MAZacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. Journal of Pediatric Endocrinology and Metabolism200619129\u2013134. (https:\/\/doi.org\/10.1515\/jpem.2006.19.2.129)"},{"key":"bib25","series-title":"Obesity Research","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/oby.2004.228","article-title":"Combined dietary and pharmacological weight management in obese hypopituitary patients","volume":"12","author":"Mersebach","year":"2004","unstructured":"Mersebach HKlose MSvendsen OLAstrup AFeldt-Rasmussen U. Combined dietary and pharmacological weight management in obese hypopituitary patients. Obesity Research2004121835\u20131843. (https:\/\/doi.org\/10.1038\/oby.2004.228)10.1038\/oby.2004.228"},{"key":"bib26","series-title":"European Journal of Pharmacology","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.03.026","article-title":"The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant","volume":"636","author":"Hansen","year":"2010","unstructured":"Hansen HHHansen GTang-Christensen MLarsen PJAxel AMDRaben AMikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European Journal of Pharmacology201063688\u201395. (https:\/\/doi.org\/10.1016\/j.ejphar.2010.03.026)10.1016\/j.ejphar.2010.03.026"},{"key":"bib27","series-title":"Current Opinion in Investigational Drugs","first-page":"1105","article-title":"Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity","volume":"10","author":"Bello","year":"2009","unstructured":"Bello NTZahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs2009101105\u20131116."},{"key":"bib28","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/npp.2010.16","article-title":"Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of \u03b11 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat","volume":"35","author":"Axel","year":"2010","unstructured":"Axel AMDMikkelsen JDHansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of \u03b11 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology2010351464\u20131476. (https:\/\/doi.org\/10.1038\/npp.2010.16)10.1038\/npp.2010.16"},{"key":"bib29","series-title":"Movement Disorders","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.21258","article-title":"Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson\u2019s disease","volume":"22","author":"Hauser","year":"2007","unstructured":"Hauser RASalin LJuhel NKonyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson\u2019s disease. Movement Disorders200722359\u2013365. (https:\/\/doi.org\/10.1002\/mds.21258)10.1002\/mds.21258"},{"key":"bib30","series-title":"Obesity","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/oby.2008.56","article-title":"Weight loss produced by Tesofensine in patients with parkinson\u2019s or Alzheimer\u2019s disease","volume":"16","author":"Astrup","year":"2008","unstructured":"Astrup AMeier DHMikkelsen BOVillumsen JSLarsen TM. Weight loss produced by Tesofensine in patients with parkinson\u2019s or Alzheimer\u2019s disease. Obesity2008161363\u20131369. (https:\/\/doi.org\/10.1038\/oby.2008.56)10.1038\/oby.2008.56"},{"key":"bib31","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","article-title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Astrup","year":"2008","unstructured":"Astrup AMadsbad SBreum LJensen TJKroustrup JPLarsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet20083721906\u20131913. (https:\/\/doi.org\/10.1016\/S0140-6736(0861525-1)10.1016\/S0140-6736(08)61525-1"},{"key":"bib32","series-title":"Obesity","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.20122","article-title":"Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats","volume":"21","author":"Bentzen","year":"2013","unstructured":"Bentzen BHGrunnet MHyveled\u2010Nielsen LSundgreen CLassen JBHansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity201321985\u2013992. (https:\/\/doi.org\/10.1002\/oby.20122)10.1002\/oby.20122"},{"key":"bib33","series-title":"Obesity","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/oby.2011.197","article-title":"The effect of tesofensine on appetite sensations","volume":"20","author":"Gilbert","year":"2012","unstructured":"Gilbert JAGasteyger CRaben AMeier DHAstrup ASj\u00f6din A. The effect of tesofensine on appetite sensations. Obesity201220553\u2013561. (https:\/\/doi.org\/10.1038\/oby.2011.197)10.1038\/oby.2011.197"},{"key":"bib34","series-title":"International Journal of Obesity and Related Metabolic Disorders","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.ijo.0801083","article-title":"Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies","volume":"24","author":"Flint","year":"2000","unstructured":"Flint ARaben ABlundell JEAstrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. International Journal of Obesity and Related Metabolic Disorders20002438\u201348. (https:\/\/doi.org\/10.1038\/sj.ijo.0801083)10.1038\/sj.ijo.0801083"},{"key":"bib35","series-title":"Journal of Clinical Epidemiology","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0895-4356(98)00107-3","article-title":"The factor structure of the SF-36 health survey in 10 countries: results from the IQOLA project. International Quality of Life Assessment","volume":"51","author":"Ware","year":"1998","unstructured":"Ware JEKosinski MGandek BAaronson NKApolone GBech PBrazier JBullinger MKaasa SLepl\u00e8ge AThe factor structure of the SF-36 health survey in 10 countries: results from the IQOLA project. International Quality of Life Assessment. Journal of Clinical Epidemiology1998511159\u20131165. (https:\/\/doi.org\/10.1016\/s0895-4356(9800107-3)10.1016\/S0895-4356(98)00107-3"},{"key":"bib36","series-title":"Journal of Clinical Epidemiology","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0895-4356(98)00092-4","article-title":"Tests of data quality, scaling assumptions, and reliability of the Danish SF-36","volume":"51","author":"Bjorner","year":"1998","unstructured":"Bjorner JBDamsgaard MTWatt TGroenvold M. Tests of data quality, scaling assumptions, and reliability of the Danish SF-36. Journal of Clinical Epidemiology1998511001\u20131011. (https:\/\/doi.org\/10.1016\/s0895-4356(9800092-4)10.1016\/S0895-4356(98)00092-4"},{"key":"bib37","series-title":"Medical Care","first-page":"AS264","article-title":"Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study","volume":"33","author":"Ware","year":"1995","unstructured":"Ware JEKosinski MBayliss MSMcHorney CARogers WHRaczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care199533AS264\u2013AS279."},{"key":"bib38","series-title":"Klinische Padiatrie","first-page":"344","article-title":"Childhood craniopharyngioma with hypothalamic obesity \u2013 no long-term weight reduction due to rehabilitation programs","volume":"226","author":"Sterkenburg","year":"2014","unstructured":"Sterkenburg ASHoffmann AGebhardt UWaldeck ESpringer SM\u00fcller HL. Childhood craniopharyngioma with hypothalamic obesity \u2013 no long-term weight reduction due to rehabilitation programs. Klinische Padiatrie2014226344\u2013350. (https:\/\/doi.org\/10.1055\/s-0034-1387747)"},{"key":"bib39","series-title":"European Journal of Clinical Nutrition","first-page":"1","article-title":"Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects","volume":"49","author":"Garrow","year":"1995","unstructured":"Garrow JSSummerbell CD. Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects. European Journal of Clinical Nutrition1995491\u201310."},{"key":"bib40","series-title":"Diabetes, Obesity and Metabolism","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/dom.12928","article-title":"A randomized, placebo-controlled trial of Beloranib for the treatment of hypothalamic injury-associated obesity","volume":"19","author":"Shoemaker","year":"2017","unstructured":"Shoemaker AProietto JAbuzzahab MJMarkovic TMalloy JKim DD. A randomized, placebo-controlled trial of Beloranib for the treatment of hypothalamic injury-associated obesity. Diabetes, Obesity and Metabolism2017191165\u20131170. (https:\/\/doi.org\/10.1111\/dom.12928)10.1111\/dom.12928"},{"key":"bib41","series-title":"Diabetes, Obesity and Metabolism","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/dom.13021","article-title":"Effects of MetAP2 inhibition on hyperphagia and body weight in Prader\u2013Willi syndrome: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"McCandless","year":"2017","unstructured":"McCandless SEYanovski JAMiller JFu CBird LMSalehi PChan CLStafford DAbuzzahab MJViskochil DEffects of MetAP2 inhibition on hyperphagia and body weight in Prader\u2013Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism2017191751\u20131761. (https:\/\/doi.org\/10.1111\/dom.13021)10.1111\/dom.13021"},{"key":"bib42","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","unstructured":"James WPTCaterson IDCoutinho WFiner NVan Gaal LFMaggioni APTorp-Pedersen CSharma AMShepherd GMRode RAEffect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine2010363905\u2013917. (https:\/\/doi.org\/10.1056\/NEJMoa1003114)10.1056\/NEJMoa1003114"},{"key":"bib43","series-title":"Diabetes, Obesity and Metabolism","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","unstructured":"Roth CLPerez FAWhitlock KBElfers CYanovski JAShoemaker AHAbuzzahab MJ. A phase 3 randomized clinical trial using a once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes, Obesity and Metabolism202123363\u2013373. (https:\/\/doi.org\/10.1111\/dom.14224)10.1111\/dom.14224"},{"key":"bib44","series-title":"Updates in Surgery","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13304-017-0425-0","article-title":"Sleeve gastrectomy leads to easy management of hormone replacement therapy and good weight loss in patients treated for craniopharyngioma","volume":"69","author":"Trotta","year":"2017","unstructured":"Trotta MDa Broi JSalerno ATesta RMMarinari GM. Sleeve gastrectomy leads to easy management of hormone replacement therapy and good weight loss in patients treated for craniopharyngioma. Updates in Surgery20176995\u201399. (https:\/\/doi.org\/10.1007\/s13304-017-0425-0)10.1007\/s13304-017-0425-0"},{"key":"bib45","series-title":"Endocrine Practice","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4158\/EP15947.OR","article-title":"Hormone substitution AFTER gastric bypass surgery in patients WITH hypopituitarism secondary to craniopharyngioma","volume":"22","author":"Wolf","year":"2016","unstructured":"Wolf PWinhofer YSmajis SKruschitz RSchindler KGessl ARiedl MVila GRaber WLanger FHormone substitution AFTER gastric bypass surgery in patients WITH hypopituitarism secondary to craniopharyngioma. Endocrine Practice201622595\u2013601. (https:\/\/doi.org\/10.4158\/EP15947.OR)10.4158\/EP15947.OR"},{"key":"bib46","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/cen.12031","article-title":"Is bariatric surgery really inefficient in hypothalamic obesity?","volume":"78","author":"Gatta","year":"2013","unstructured":"Gatta BNunes MLBailacq\u2010Auder CEtchechoury LCollet DTabarin A. Is bariatric surgery really inefficient in hypothalamic obesity?Clinical Endocrinology201378636\u2013638. (https:\/\/doi.org\/10.1111\/cen.12031)10.1111\/cen.12031"},{"key":"bib47","series-title":"Lancet","article-title":"Expression of concern \u2013 effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","volume":"381","year":"2013","unstructured":"The Lancet Editors. Expression of concern \u2013 effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet2013381 1167. (https:\/\/doi.org\/10.1016\/S0140-6736(1360778-3)"},{"key":"bib48","series-title":"Lancet","article-title":"Under-reporting of adverse effects of tesofensine","volume":"382","author":"Astrup","year":"2013","unstructured":"Astrup AMadsbad SBreum LJensen TJKroustrup JPLarsen TM. Under-reporting of adverse effects of tesofensine. Lancet2013382 127. (https:\/\/doi.org\/10.1016\/S0140-6736(1361563-9)"},{"key":"bib49","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1530\/EJE-13-1025","article-title":"Sleep-wake and melatonin pattern in craniopharyngioma patients","volume":"170","author":"Pickering","year":"2014","unstructured":"Pickering LJennum PGammeltoft SPoulsgaard LFeldt-Rasmussen UKlose M. Sleep-wake and melatonin pattern in craniopharyngioma patients. European Journal of Endocrinology2014170873\u2013884. (https:\/\/doi.org\/10.1530\/EJE-13-1025)10.1530\/EJE-13-1025"},{"key":"bib50","series-title":"PLoS ONE","article-title":"Cardiac autonomic dysfunction is associated with hypothalamic damage in patients with childhood-onset craniopharyngioma","volume":"16","author":"Jung","year":"2021","unstructured":"Jung HWKim HYKim JYCheon JEKim IOKim SKShin CHYang SWLee YA. Cardiac autonomic dysfunction is associated with hypothalamic damage in patients with childhood-onset craniopharyngioma. PLoS ONE202116 e0246789. (https:\/\/doi.org\/10.1371\/journal.pone.0246789)"},{"key":"bib51","series-title":"Journal of General Internal Medicine","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","unstructured":"Kroenke KSpitzer RLWilliams JBW. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine200116606\u2013613. (https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x)10.1046\/j.1525-1497.2001.016009606.x"},{"key":"bib52","article-title":"PHQ9_Danish for Denmark.pdf","unstructured":"PHQ9_Danish for Denmark.pdf [Internet]. [cited 2021 Jul 5]. (available at: https:\/\/www.phqscreeners.com\/images\/sites\/g\/files\/g10060481\/f\/201412\/PHQ9_Danish%20for%20Denmark.pdf)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/186\/6\/EJE-21-0972.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/186\/6\/EJE-21-0972.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/186\/6\/EJE-21-0972.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:17:23Z","timestamp":1676391443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/186\/6\/687\/6853697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":52,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/eje-21-0972","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}